NanoCell Therapeutics, Inc.
NanoCell Therapeutics is dedicated to developing in vivo gene therapies using non-viral, DNA-based, cell-directed technology platforms. Their mission is to transform cell and gene therapy by making treatments more scalable, affordable, and safe, with a focus on global patient access. They leverage proprietary lipid nanoparticle technology to precisely target and modify cells within the patient's body, aiming to revolutionize cancer, autoimmune, and inherited disease treatments.
Industries
Nr. of Employees
small (1-50)
NanoCell Therapeutics, Inc.
150 N Radnor Chester Road, Suite A210, Wayne PA 19087, United States
Products
In‑vivo CAR-T clinical candidate targeting CD22 for diffuse large B‑cell lymphoma
A lead clinical-stage program that uses non-viral DNA LNP delivery to generate CAR-expressing T cells in vivo targeting CD22 for the treatment of diffuse large B‑cell lymphoma.
In‑vivo CAR-T clinical candidate targeting CD22 for diffuse large B‑cell lymphoma
A lead clinical-stage program that uses non-viral DNA LNP delivery to generate CAR-expressing T cells in vivo targeting CD22 for the treatment of diffuse large B‑cell lymphoma.
Services
Partnerships with academic and industry groups to apply the non-viral DNA LNP platform to oncology and autoimmune disease programs.
Design and conduct of animal studies and translational experiments to evaluate non-viral DNA delivery and in‑vivo generation of engineered immune cells.
Partnerships with academic and industry groups to apply the non-viral DNA LNP platform to oncology and autoimmune disease programs.
Design and conduct of animal studies and translational experiments to evaluate non-viral DNA delivery and in‑vivo generation of engineered immune cells.
Expertise Areas
- In‑vivo gene therapy development
- Non-viral nucleic acid delivery
- Lipid nanoparticle formulation and targeting
- Vector engineering (minicircle DNA)
Key Technologies
- Lipid nanoparticle (LNP) formulations
- Cell-targeting ligand/binder technology
- Minicircle DNA vectors
- RNA-format transposase
News & Updates
NanoCell secured seed-extension financing to support the development of their lead clinical candidate targeting B cell malignancies.
NanoCell announced their upcoming participation in investor conferences to engage with stakeholders.
NanoCell released data demonstrating successful non-viral DNA delivery for in vivo CAR-T cell generation in animal models.
NanoCell secured seed-extension financing to support the development of their lead clinical candidate targeting B cell malignancies.
NanoCell announced their upcoming participation in investor conferences to engage with stakeholders.
NanoCell released data demonstrating successful non-viral DNA delivery for in vivo CAR-T cell generation in animal models.